Oncology Central

Checkpoint blockade immunotherapy doubles survival for melanoma brain metastases patients

A team of researchers from Brigham and Women’s Hospital (MA, USA) have demonstrated that checkpoint blockade immunotherapy (CBI) provides a significant improvement in overall survival for patients with melanoma brain metastases. The findings were recently published in Cancer Immunology Research.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.